Screening for adverse pregnancy outcome at early gestational age

Cuckle, 1996, Established markers in second trimester maternal serum, Early Hum Dev, 47 Suppl, S27, 10.1016/S0378-3782(96)01814-2 Muller, 1996, Maternal serum markers for fetal trisomy 21 screening, Eur J Obstet Gynecol Reprod Biol, 65, 3, 10.1016/0028-2243(95)02293-2 Spencer, 1999, A screening program for trisomy 21 at 10–14weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A, Ultrasound Obstet Gynecol, 13, 231, 10.1046/j.1469-0705.1999.13040231.x Cuckle, 2000, Biochemical screening for Down syndrome, Eur J Obstet Gynecol Reprod Biol, 92, 97, 10.1016/S0301-2115(00)00431-0 Benacerraf, 1985, A sonographic sign for the detection in the second trimester of the fetus with Down's syndrome, Am J Obstet Gynecol, 151, 1078, 10.1016/0002-9378(85)90385-0 Vintzileos, 1995, Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography, Am J Obstet Gynecol, 172, 837, 10.1016/0002-9378(95)90008-X Nyberg, 1998, Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases, Ultrasound Obstet Gynecol, 12, 8, 10.1046/j.1469-0705.1998.12010008.x Winter, 2000, The “genetic sonogram”: comparison of the index scoring system with the age-adjusted US risk assessment, Radiology, 215, 775, 10.1148/radiology.215.3.r00ma36775 Nyberg, 2001, Sonographic markers of fetal trisomies: second trimester, J Ultrasound Med, 20, 655, 10.7863/jum.2001.20.6.655 Bromley, 2002, The genetic sonogram: a method of risk assessment for Down syndrome in the second trimester, J Ultrasound Med, 21, 1087, 10.7863/jum.2002.21.10.1087 Bahado-Singh, 2002, The comprehensive midtrimester test: high-sensitivity Down syndrome test, Am J Obstet Gynecol, 186, 803, 10.1067/mob.2002.121651 Schluter, 2005, Mid trimester sonographic findings for the prediction of Down syndrome in a sonographically screened population, Am J Obstet Gynecol, 192, 10, 10.1016/j.ajog.2004.08.036 Tul, 1999, Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and pregnancy associated plasma protein-A at 10–14weeks of gestation, Prenat Diagn, 19, 1035, 10.1002/(SICI)1097-0223(199911)19:11<1035::AID-PD694>3.0.CO;2-2 Spencer, 2000, Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and pregnancy associated plasma protein A at 10–14weeks of gestation, Prenat Diagn, 20, 411, 10.1002/(SICI)1097-0223(200005)20:5<411::AID-PD822>3.0.CO;2-2 Spencer, 2000, Screening for triploidy by fetal nuchal translucency and maternal serum free β Human chorionic gonadotropin and pregnancy associated plasma protein-A at 10–14 weeks of gestation, Prenat Diagn, 20, 495, 10.1002/1097-0223(200006)20:6<495::AID-PD846>3.0.CO;2-U Spencer, 2003, Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience, BJOG, 110, 281, 10.1046/j.1471-0528.2003.02246.x Avgidou, 2005, Prospective first-trimester screening for trisomy 21 in 30, 564 pregnancies, Am J Obstet Gynecol, 192, 1761, 10.1016/j.ajog.2005.03.021 Nicolaides, 2005, Multitcenter study of first-trimester screening for trisomy 21 in 75, 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening, Ultrasound Obstet Gynecol, 25, 221, 10.1002/uog.1860 Heckerling, 1994, Preferences of pregnant women for amniocentesis or chorionic villus sampling for prenatal testing: comparison of patients' choices and those of a decision-analytic model, J Clin Epidemiol, 47, 1215, 10.1016/0895-4356(94)90126-0 Kandel, 2003, Late termination of pregnancy. Professional dilemmas, Sci World J, 3, 903, 10.1100/tsw.2003.81 Ville, 2010, Prima facie, Ultrasound Obstet Gynecol, 35, 1, 10.1002/uog.7526 Chaoui, 2010, From nuchal translucency to intracranial translucency: towards the early detection of spina bifida, Ultrasound Obstet Gynecol, 35, 133, 10.1002/uog.7552 Nicolaides, 2004, Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities, Am J Obstet Gynecol, 191, 45, 10.1016/j.ajog.2004.03.090 Salomon, 2009, The impact of crown rump length measurement error on combined Down syndrome screening: a simulation study, Ultrasound Obstet Gynecol, 33, 506, 10.1002/uog.6371 Snijders, 1998, UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10–14weeks of gestation, Lancet, 352, 343, 10.1016/S0140-6736(97)11280-6 Souka, 2005, Increased nuchal translucency with normal karyotype, Am J Obstet Gynecol, 192, 1005, 10.1016/j.ajog.2004.12.093 Makrydimas, 2003, Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis, Am J Obstet Gynecol, 189, 1330, 10.1067/S0002-9378(03)00645-8 Souka, 1998, Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency at 10–14weeks of gestation, Ultrasound Obstet Gynecol, 11, 391, 10.1046/j.1469-0705.1998.11060391.x Souka, 2001, Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester, Ultrasound Obstet Gynecol, 18, 9, 10.1046/j.1469-0705.2001.00454.x Michailidis, 2001, Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses, Ultrasound Obstet Gynecol, 17, 102, 10.1046/j.1469-0705.2001.00341.x Spencer, 2007, Aneuploidy screening in the first trimester, Am J Med Genet C Semin Med Genet, 145c, 18, 10.1002/ajmg.c.30119 Hook, 1992, Prevalence, risks and recurrence, 351 Egan, 2000, Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997, Obstet Gynecol, 96, 979, 10.1016/S0029-7844(00)01044-9 Snijders, 1995, Maternal age and gestational age specific risks for chromosomal defects, Fetal Diag Ther, 10, 356, 10.1159/000264259 Aitken, 2002, Prenatal screening for neural tube defects and aneuploidy, 763 Spencer, 2009, Maternal serum screening marker levels in women with a previous aneuploidy pregnancy, Prenat Diagn, 29, 1242, 10.1002/pd.2395 Muller, 2002, Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854, 902 patients, Prenat Diagn, 22, 925, 10.1002/pd.438 Bindra, 2002, One-stop clinic for assessment of risk for trisomy 21 at 11–14weeks: a prospective study of 15 030 pregnancies, Ultrasound Obstet Gynecol, 20, 219, 10.1046/j.1469-0705.2002.00808.x Kagan, 2008, Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A, Ultrasound Obstet Gynecol, 31, 618, 10.1002/uog.5331 Souka, 2004, Assessment of fetal anatomy at the 11–14-week ultrasound examination, Ultrasound Obstet Gynecol, 24, 730, 10.1002/uog.1775 Wortelboer, 2009, First-trimester Down syndrome screening performance in the Dutch population; how to achieve further improvement?, Prenat Diagn, 29, 588, 10.1002/pd.2247 Wapner, 2003, First-trimester screening for trisomies 21 and 18, N Engl J Med, 349, 1405, 10.1056/NEJMoa025273 Wald, 2003, Antenatal screening for Down's syndrome with the quadruple test, Lancet, 361, 835, 10.1016/S0140-6736(03)12680-3 Malone, 2005, First-trimester or second-trimester screening, or both, for Down's syndrome, N Engl J Med, 353, 2001, 10.1056/NEJMoa043693 Wald, 2003, First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS), J Med Screen, 10, 56, 10.1258/096914103321824133 Breathnach, 2007, Screening for aneuploidy in first- and second-trimester: is there an optimal paradigm?, Curr Opin Obstet Gynecol, 19, 176, 10.1097/GCO.0b013e3280895e00 Wright, 2004, Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening, Prenat Diagn, 24, 762, 10.1002/pd.974 Cuckle, 2005, Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters, Semin Perinatol, 29, 252, 10.1053/j.semperi.2005.05.004 Ball, 2007, First- and second-trimester evaluation of risk for Down syndrome, Obstet Gynecol, 110, 10, 10.1097/01.AOG.0000263470.89007.e3 Reddy, 2007, Comparison of first and second trimester aneuploidy risk assessment, Clin Obstet Gynecol, 50, 442, 10.1097/GRF.0b013e31804c9b99 Wald, 2006, Sequential and contingent prenatal screening for Down syndrome, Prenat Diagn, 26, 769, 10.1002/pd.1498 Palomaki, 2006, Comparing three screening strategies for combining first- and second-trimester Down syndrome markers, Obstet Gynecol, 107, 367, 10.1097/01.AOG.0000195061.48747.f4 Maiz, 2009, Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11–13weeks of gestation, Ultrasound Obstet Gynecol, 33, 512, 10.1002/uog.6330 Kagan, 2009, Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6weeks of gestation, Ultrasound Obstet Gynecol, 33, 18, 10.1002/uog.6264 Spencer, 2000, Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester, Prenat Diagn, 20, 390, 10.1002/(SICI)1097-0223(200005)20:5<390::AID-PD824>3.0.CO;2-B Urban, 2001, Ultrasonographic and clinical appearance of a 22-week-old fetus with Brachmann-de Lange syndrome, Am J Med Genet, 102, 73, 10.1002/1096-8628(20010722)102:1<73::AID-AJMG1419>3.0.CO;2-H Huang, 2002, Abnormal first-trimester fetal nuchal translucency and Cornelia De Lange syndrome, Obstet Gynecol, 99, 956, 10.1016/S0029-7844(02)01982-8 Aitken, 1999, Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies, Prenat Diagn, 19, 706, 10.1002/(SICI)1097-0223(199908)19:8<706::AID-PD613>3.0.CO;2-W Arbuzova, 2003, Low first-trimester pregnancy-associated plasma protein-A and Cornelia de Lange syndrome, Prenat Diagn, 23, 864, 10.1002/pd.690 Spencer, 2008, Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers, Prenat Diagn, 28, 49, 10.1002/pd.1923 Fisk, 1995, Prenatal determination of chorionicity and zygosity, 56 Spencer, 2010, First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers, Prenat Diagn, 30, 235, 10.1002/pd.2445 Spencer, 2003, Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience, BJOG, 110, 276, 10.1046/j.1471-0528.2003.02222.x Gekas, 2009, Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation, BMJ, 338, b138, 10.1136/bmj.b138 Mulvey, 2003, Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate?, Prenat Diagn, 23, 828, 10.1002/pd.701 Spencer, 2004, Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies, Ultrasound Obstet Gynecol, 24, 10.1002/uog.1768 Nicolaides, 2005, Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21, Am J Obstet Gynecol, 193, 322, 10.1016/j.ajog.2005.02.134 Sibai, 2005, Pre-eclampsia, Lancet, 365, 785, 10.1016/S0140-6736(05)71003-5 Ong, 2000, First trimester maternal serum free human chorionic gonadotropin and pregnancy associated plasma protein A as predictors of pregnancy complications, BJOG, 107, 1265, 10.1111/j.1471-0528.2000.tb11618.x Yaron, 2002, First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome, Fetal Diagn Ther, 17, 352, 10.1159/000065384 Smith, 2006, Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome, Obstet Gynecol, 107, 161, 10.1097/01.AOG.0000191302.79560.d8 Dugoff, 2004, First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial), Am J Obstet Gynecol, 191, 1446, 10.1016/j.ajog.2004.06.052 Spencer, 2008, Low levels of maternal serum PAPP-A in early pregnancy and the risk of adverse outcomes, Prenat Diagn, 28, 1029, 10.1002/pd.2116 Kang, 2008, Down syndrome biochemical markers and screening for pre-eclampsia at first and second trimester: correlation with the week of onset and the severity, Prenat Diagn, 28, 704, 10.1002/pd.1997 Spencer, 2008, First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses, Ultrasound Obstet Gynecol, 31, 15, 10.1002/uog.5165 Goetzl, 2004, Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss, Obstet Gynecol, 104, 30, 10.1097/01.AOG.0000129969.78308.4f Cuckle, 2003, Frequency and clinical consequences of extremely high maternal serum PAPP-A levels, Prenat Diagn, 23, 385, 10.1002/pd.600 Tul, 2003, Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A, Prenat Diagn, 23, 990, 10.1002/pd.735 Papageorghiou, 2004, The role of uterine artery Doppler in predicting adverse pregnancy outcome, Best Pract Res Clin Obstet Gynaecol, 18, 383, 10.1016/j.bpobgyn.2004.02.003 Spencer, 2005, Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler, Prenat Diagn, 25, 949, 10.1002/pd.1251 Poon, 2010, Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13weeks, Prenat Diagn, 30, 216, 10.1002/pd.2440 Nicolaides, 2006, A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound, Ultrasound Obstet Gynecol, 27, 13, 10.1002/uog.2686 Krantz, 2004, Association of extreme first-trimester free human chorionic gonadotropin-b, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes, Am J Obstet Gynecol, 191, 1452, 10.1016/j.ajog.2004.05.068 Goetzinger, 2009, The efficiency of first-trimester serum analytes and maternal characteristics in predicting fetal growth disorders, Am J Obstet Gynecol, 201, 412.e1-6, 10.1016/j.ajog.2009.07.016 Spencer, 2006, First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death, Ultrasound Obstet Gynecol, 28, 637, 10.1002/uog.3809 Rissanen, 2007, First trimester Down's syndrome screening shows high detection rate for trisomy 21, but poor performance in structural abnormalities—regional outcome results, Fetal Diagn Ther, 22, 45, 10.1159/000095843 Cuckle, 1999, Low maternal serum PAPP-A and fetal viability, Prenat Diagn, 19, 788, 10.1002/(SICI)1097-0223(199908)19:8<788::AID-PD609>3.0.CO;2-Q Smith, 2004, First-trimester placentation and the risk of antepartum stillbirth, JAMA, 292, 2249, 10.1001/jama.292.18.2249 Steer, 2005, The epidemiology of preterm labour, BJOG, 112, 1, 10.1111/j.1471-0528.2005.00575.x